Sugimoto, Kiichi
Sakamoto, Kazuhiro
Tsuchiya, Takashi
Takahashi, Takao
Ohge, Hiroki
Sato, Toshihiko
Taguri, Masataka
Morita, Satoshi
Sadahiro, Sotaro
Article History
Accepted: 26 October 2023
First Online: 31 October 2023
Declarations
:
: The protocol for this study was approved by the institutional review boards of the participating hospitals. This study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Registration: JFMC46-1201 (Japan Registry of Clinical Trials jRCTs031180155 [date of registration: 25/02/2019] and UMIN Clinical Trials Registry UMIN000007783 [date of registration: 18/04/2012]) was a multi-institutional study approved by the National Cancer Center Hospital East Certified Review Board (CRB3180009).
: Written informed consent was obtained from all patients before enrollment.
: Kazuhiro Sakamoto has received Research expenses, Scholarship donations from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Asahi Kasei Pharma Co., Ltd. and Taiho Pharmaceutical Co., Ltd. Takao Takahashi was awarded an endowed chair from Yakult Co., Ltd. Satoshi Morita has received Lecture fees, etc from AstraZeneca K.K., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan lnc., Taiho Pharmaceutical Co., Ltd. The remaining authors have stated that they have no conflicts of interest.
: The funding source had no role in the study design, data collection, analysis and interpretation, or decision to submit results for presentation or publication, other than providing information on the efficacy and safety of UFT/LV.